<DOC>
	<DOC>NCT01424124</DOC>
	<brief_summary>The main objective is to evaluate the safety/tolerability and efficacy of YHD001 compared to singulair or placebo in patients (n=96) with partially controlled asthma. The study will conduct with 4 comparative groups orally treated with YHD001 dose level 1(t.i.d.), YHD001 dose level 2(t.i.d.), singulair 10mg(q.d.) or Placebo for 8 weeks.</brief_summary>
	<brief_title>Safety and Efficacy of YHD001 in Asthma</brief_title>
	<detailed_description>Singulair: Montelukast sodium (leukotriene modulator)</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Provision of signed written informed consent Acceptable medical history, physical exam,laboratory tests and EKG, during screening Nonsmoking (for longer than 1 year) patients with asthma Reversible airways obstruction (an increase in FEV1 absolute value of 12% or greater) 20 to 30 minutes after inhalation of bâˆ’agonist FEV1 between 50% and 85% of the predicted value (withholding shortacting, inhaled b2adrenergic agonist for 6 hours) History of any clinically significant disease History of drug/chemical/alcohol abuse Active upper respiratory tract infection within 3 weeks, emergency room treatment for asthma within 1 month, or hospitalization for asthma within 3 months of the prestudy visit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>